17,261 trials
Molybdenum Cofactor Deficiency, Type A
Primary: Safety of ORGN001 (Formerly ALXN1101) — 1; 5; 6; 2 events
Non Small Cell Lung Cancer
Primary: Objective Response Rate as Assessed by the Investigator Using Response Evaluation Criteria In Solid Tumors (RECIST 1.1) — 8 Participants
Metastatic Renal Cell Carcinoma
Primary: Efficacy of Pembrolizumab and Cabozantinib Based on Objective Response Rate — 65.8; 0 % of patients
Type 2 Diabetes
Primary: Change From Baseline in HbA1c in LY3502970 as Compared to Placebo — -1.19; -1.91; -1.79; -2.03 Percentage of HbA1c — p=<0.001
Inflammatory Bowel Diseases · Ulcerative Colitis · Crohn Disease
Primary: 1. Safety and Tolerability of Universal Donor FMT Compared to Placebo: FMT-related Adverse Events Grade 2 or Above — 4; 0 Participants
Systemic Allergic Reaction
Primary: Proportion of Participants Who Had Recurrent Systemic Allergic Reaction to Vaccine — 0.125 Proportion of participants
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Primary: Cohort 1: Percentage of Participants With Complete Response (CR) for B-cell Acute Lymphoblastic Leukemia (ALL) — 0 Percentage of participants
Dry Eye
Primary: Inferior Corneal Staining Score — -0.08; -0.03 units on a scale
Urothelial Carcinoma
Primary: Objective Response Rate (ORR) Based on RECIST 1.1 (Substudies 1,3,4 and 5) — 9.4; 0.0; 14.3; 0.0 Percentage of participants
Chronic Diarrhea · Irritable Bowel Syndrome With Diarrhea · Bile Acid Malabsorption
Primary: Fasting Serum C4 Levels — 2.2; 50.4 ng/ML
Sickle Cell Disease
Primary: Event-free Survival (EFS) Rate — 5 Participants
Acute Stroke · Endovascular Thrombectomy
Primary: Final Infarct Volume — 46.4; 50.7; 32.4 Cubic Centimeters
Diabetic Macular Edema
Primary: Number of Participants With Adverse Events — 20; 16; 19; 16 Participants
Duchenne Muscular Dystrophy
Primary: Change in Dystrophin Expression From Baseline Following Treatment With Either AMONDYS 45 (Previously Casimersen), EXONDYS 51 (Previously Eteplirsen ), or VYONDYS 53…
Heart Failure With Preserved Ejection Fraction
Primary: Pulmonary Capillary Wedge Pressure (PCWP) at Maximal Exercise — -6.6; -0.4 mmHg — p=0.027